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Abstract  
Introduction 
Adolescent HPV vaccination rates lag behind other vaccinations, partly due to missed 
opportunities for vaccination and lack of provider recommendation.  This study evaluated the 
rates of HPV vaccination among adolescents with physical and mental limitation and controls, 
and evaluated differences in parental knowledge and reasons for nonvaccination between groups. 
Materials and Methods 
A retrospective chart review was performed on female patients age 12-18 presenting to pediatric 
or gynecology clinics in 2012.  Those subjects with a diagnosis of mental or physical limitation 
were classified as “affected”.  HPV vaccination rates were compared between affected and 
control groups.  Parents of affected subjects were contacted by phone and surveyed regarding 
HPV knowledge and reasons for nonvaccination.  Parents of controls were contacted at a 2:1 
ratio and were administered the same survey.   
Results 
1673 females were included in the study; 72 (4.3%) had mental/physical impairment (affected).  
Overall, 944 (56.4%) subjects had initiated HPV vaccination and 653 (39%) had completed the 
three dose series.  When comparing affected subjects to controls, the control group was more 
likely to have received any HPV vaccination (RR 1.32,  95% CI 1.013, 1.73).  Parents of 21 
affected subjects and 44 control subjects were contacted by phone.  No differences were found in 
parent knowledge of HPV or importance of vaccination to a child’s health.  There were no 
differences in reasons for nonvaccination between groups, but for both groups “lack of provider 
recommendation” was in the top two choices. That the vaccine was “not needed” was the other 
main reason given for nonvaccination in the affected group, while the control group main reason 
for nonvaccination was “concerns for safety”.   
Discussion 
Adolescents with mental or physical limitation may be less likely to receive HPV vaccination.  
Lack of provider recommendation remains one of the primary reasons those in this population do 
not receive HPV vaccination.  
Keywords   
Human papillomavirus, vaccination, mental limitation, physical limitation 
Introduction 
Human papillomavirus (HPV) is associated with the development of anogenital cancers such as 
cervical, vaginal, vulvar, penile and anal.  HPV also causes genital warts and certain types of 
oropharyngeal cancer.1  The Advisory Committee on Immunization Practices recommends HPV 
vaccination for girls and boys at the target age of 11-12, with catch up vaccination up to age 26.  
The vaccine was initially recommended for all ages as a series of three injections over a six 
month period of time.2  In 2016, these recommendations changed to a two dose series for those 
initiating vaccination under age 15.3   HPV vaccination has been demonstrated to be safe and 
effective at reducing the risk of genital warts and HPV associated cancers.4, 5  Despite this 
demonstrated safety and efficacy, in 2015, 62.8% of females in a nationwide sample received at 
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least one HPV vaccination, with only 41.9% receiving all three injections.6  While these numbers 
have increased from recent years, HPV vaccination still lags behind other vaccine uptake and the 
Healthy People target of 80%.6 In one national survey, the most common reasons for parents 
choosing not to vaccinate against HPV were 1) they felt the vaccine is not needed, 2) their child 
is not sexually active, 3) parental concerns about safety or side effects, 4) lack of knowledge 
about the vaccine, and 5) the vaccine was not recommended by their provider.7   
HPV vaccination recommendations include those children and adolescents with special health 
care needs.  It was our hypothesis that among children with physical and mental limitation, HPV 
vaccination would be lower than among children without these limitations.  One small study 
demonstrated that parents of children with special health care needs have difficulty accepting the 
HPV vaccine primarily due to the perception that their child was unlikely to be sexually active.8  
However, another study including a sample of >20,000 7-12th grade females concluded that those 
with mobility impairments and those with learning disabilities are just as likely as their peers to 
be sexually active.9 It is also known that adolescents with disabilities are at increased risk of 
being sexually abused compared to the general population.  In one study, 16.6% of children with 
autism had been sexually abused per report from caregivers.10 
This study evaluated the rates of HPV vaccination among adolescents with physical and mental 
limitation compared to adolescents without these limitations.  The aim was to evaluate if 
vaccination rates were different, and if reasons for nonvaccination were different between the 
two groups. 
Materials and Methods 
This study is a retrospective chart review and cross sectional survey that assessed the vaccine 
rate among female patients with mental and physical limitation compared to those without these 
limitations.  Charts of female patients ages 12-18 years presenting for well child visits or routine 
health maintenance visits from January 1, 2012 through December 31, 2012 were reviewed.  
This review included female patients from the pediatric and gynecology clinics at an academic 
institution.  The chart review and survey were conducted in 2015.  The study year of 2012 was 
chosen in order to give those patients presenting at the end of the year adequate time for vaccine 
series completion.  Only females were included in this study, as the HPV vaccine 
recommendation for males was not made routine until 2011.  Patients reviewed from the 
gynecology clinics were nonpregnant adolescents within the specified age group.   
Patients were identified by using CPT codes for well child visits.  Data was collected on the 
patients’ age, diagnoses, number of vaccinations in the series, and dates of vaccinations.  Mental 
and physical delays were determined by a chart review using the patients past medical history 
and diagnosis codes. Those subjects with either a diagnosis of mental or physical limitation are 
referred to as the “affected” group.  These patient diagnoses were recorded and discussed among 
the research team.  Those patients agreed as having a diagnosis consistent with mental or 
physical limitation were placed in the affected group.   Patients without diagnoses of mental of 
physical limitation were placed in the control group.  Rates of HPV vaccination among the 
affected group and control group were compared.    
Parents or guardians of those subjects in the affected group not receiving HPV vaccination were 
then contacted by phone and a short survey was conducted.  Up to three attempts were made to 
contact each of the unvaccinated subjects’ parent in the affected group.  The phone survey lasted 
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five minutes and included single answer questions such as true/false questions regarding 
knowledge of HPV transmission and vaccination.  The phone survey also included parental 
perception of vaccine safety and importance measured by Likert scale. Reasons for 
nonvaccination against HPV were also assessed by multiple choice based on the most cited 
reasons of 1) not needed or necessary, 2) child not sexually active, 3) concerns for safety or side 
effects, 4) lack of knowledge about the vaccine, and 5) not recommended by medical provider.  
For this question, they were asked to cite the single main reason why their child did not receive 
the HPV vaccine.   
Parents of subjects in the unvaccinated control group were also contacted by phone for the same 
survey assessment.  As it was not feasible to contact the entire control population, control 
subjects were age matched in a 2:1 ratio to the affected group for comparison.  Parents or 
guardians of this control group were contacted using the same survey.  Vaccine knowledge, 
reasons for nonvaccination, and perception of vaccine safety and importance were compared 
between groups.  Between group data was analyzed comparing proportions using Pearson Chi 
Square or Fishers exact test when appropriate.  The T-test was used for continuous variables.  
SPSS version 22 was used for all statistical analyses.  Institutional Review Board approval was 
obtained prior to the study.   
Results 
The chart review yielded 1673 females that met criteria for well child visits presenting to either 
the pediatric or gynecology clinics during the designated study period.  Of these females, 72 
(4.3%) were found to have mental/physical impairment.  These subjects included diagnoses such 
as cerebral palsy, Rett syndrome, Noonan syndrome, autism, Down Syndrome, Asperger 
syndrome, arthrogryposis, muscular dystrophy, and mental retardation.  Overall, 944 (56.4%) 
subjects had initiated HPV vaccination and 653 (39%) had completed the three dose series.  The 
control group age was slightly older than the affected group age during the study period (15.9 
(SD 2.7) vs 14.8 (SD 2.4); p=0.058).  However, the mean age at first HPV injection did not 
differ between control and affected group (12.2 (SD 4.0) vs 12.2 (SD 1.8); p=0.79).   
In the control group, 913 subjects out of 1601 (57%) had at least one HPV vaccination 
documented.  In the affected group, 31 subjects out of 72 (43%) had at least one HPV 
vaccination documented.  When comparing affected subjects to controls, the control group was 
more likely to have received any HPV vaccination (RR 1.32  95% CI 1.013, 1.73, Table 1).  
Among those that had initiated vaccination, similar percentages were seen between groups of 
those completing all three doses (22 (79.9%) affected vs 631 (69%) controls ; p=0.83).   
 Table 1:  Vaccination rates between affected and control groups 
 Vaccinated Not Vaccinated  
Affected Group (n=72) 
 
31 (43%) 41 (57%)  
Control Group (n=1601) 
 
913 (57%) 688 (43%) RR 1.32 (1.013, 1.73) 
 
There were 41 out of 72 affected subjects that did not receive any vaccine.  Of these subjects 
only 21 parents (51.2%) were able to be contacted by phone survey.  Out of the 688 controls not 
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vaccinated, subjects were age matched to the affected group in a 2:1 ratio.  Survey data was 
collected from a resultant 44 unvaccinated control parents.  HPV knowledge was similar among 
parents of the affected group and controls, except for the True/False question “HPV causes 
cough”, which was answered incorrectly by more parents in the control group (Table 2).  Only 
33.3% of parents in the affected group and 45.5% of parents in the control group answered 
correctly that “HPV causes genital warts”.  Awareness increased that “HPV causes cervical 
cancer” with 81% of affected and 72.7% of control group answering correctly.  However, 
awareness of oropharyngeal cancers linked to HPV was low in both groups (28.6% of affected 
and 20.5% of controls).  The majority in both groups were aware that HPV was transmitted by 
sexual activity.   
Table 2: Comparison of HPV knowledge between affected and control groups. Responses listed    
               as % (n).     
True/False Question Affected Group  (n=21) Controls (n=44) p 
value 
 
HPV causes cough  
(False) 
% Yes % No 
0 (0) 100 (21) 
 
% Yes % No 
31.8 (14) 68.2 (30) 
 
 
0.003 
HPV causes genital warts 
(True) 
33.3 (7) 66.7 (14) 
 
45.5 (20) 54.5 (24)  
 
0.354 
HPV causes cervical cancer 
(True) 
81 (14) 19 (4) 
 
72.7 (32) 27.3 (12) 
 
0.472 
HPV causes heart attacks 
(False) 
9.5 (2) 90.5 (19) 
 
22.7 (10) 77.3 (34) 
 
0.309 
HPV causes throat cancer 
(True) 
28.6 (6) 71.4 (15) 
 
20.5 (9) 79.5 (35) 
 
0.535 
People can have HPV and 
have no symptoms  
(True) 
61.9 (13) 38.1 (8) 
 
43.2 (19) 56.8 (25) 
 
0.158 
People can get HPV from 
sexual activity  
(True) 
100 (21) 0 (0) 
 
84.1 (37) 15.9 (7) 
 
0.086 
People can get HPV from 
someone coughing or 
sneezing on them 
(False) 
4.8 (1) 95.2 (20) 
 
15.9 (7) 84.1 (37) 
 
0.259 
People can get HPV from 
undercooked meat  
(False) 
4.8 (1) 95.2 (20) 
 
18.2 (8) 81.8 (36) 
 
0.251 
 
There were no differences in chosen reasons not to vaccinate their child between groups (Table 
3).  Among parents in the affected group, the two most commonly cited reasons were that the 
vaccine was not needed (n=7) and that the vaccine was not recommended by their medical 
provider (n=7).  In the control group, the two most cited reasons were safety concerns (n=15) 
and lack of recommendation from their provider (n=10).   
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Table 3: Reasons chosen for HPV nonvaccination compared between groups.  
Reason Affected (n=21) Control (n=44) p value 
Not needed 33.3% (7) 15.9% (7) 0.195 
Child not sexually active 9.5% (2) 15.9% (7) 0.706 
Concern for safety or side effects 19% (4) 34.1% (15) 0.256 
Lack of knowledge about the vaccine 4.8% (1) 11.4% (5) 0.655 
Not recommended by medical provider 33.3% (7) 22.7% (10) 0.381 
 
Thirty four (77.3%) of the control group and 17 (81%) of affected group felt that vaccines were 
very important to their child’s health (p= 0.736).  Those that felt vaccines were “very safe” and 
“somewhat safe” were also comparable between control and affected groups: (19 (43.2%) vs 11 
(52.4%); p= 0.487 and 22 (50%) vs 9 (42.9%); p=0.59, respectively, Table 4).    
 
Table 4: Comparison of parent responses to Likert scale questions of “How important are 
vaccines to your child’s health?”, and “In general, how safe do you think vaccines are?”.   
Response Affected (n=21) Control (n=44) p value 
Very important 81% (17) 77.3% (34) 0.736 
Very Safe 52.4% (11) 43.2% (19) 0.487 
Somewhat safe 42.9% (9) 50% (22) 0.59 
 
Discussion 
In this study we found that females with mental or physical limitation are less likely to receive 
HPV vaccination compared to those without these limitations.  Our study population had overall 
comparable rates of HPV vaccine initiation (56.4%) and completion (39%) compared to national 
reported rates.  Among those initiating vaccination, we also found similar completion rates 
between the two groups.  While no significant differences between groups were found with 
parental knowledge and reasons for nonvaccination, this affected population may have other 
barriers not elucidated by this study design.   
This study is limited by the overall number of subjects included.  Our affected subjects 
comprised 4.3% of the total study population, which is similar to percentages in other studies 
looking at adolescents within a population with physical or mental limitation. 9  Due to the small 
number of surveys able to be completed on the affected population, we may not have had enough 
power to detect any differences from the control group.  A 2:1 matching approach was done on 
the control group to collect enough surveys for comparison.  This was done as collecting phone 
surveys on all 688 unvaccinated controls was not feasible.   
The retrospective chart design also adds limitation to study. While each chart was reviewed and 
the research team agreed whether or not to classify a patient as “affected” or not, this approach is 
somewhat subjective.  Other factors such as insurance status, parental age, and subject sexual 
activity were not collected, but all could affect vaccine adherence or relevance.  Parental 
knowledge was assessed on HPV vaccination, but education level and knowledge of other 
vaccinations was not obtained.   
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Despite these limitations, there is paucity of data regarding HPV vaccination among adolescents 
with special needs.  The only contraindication to HPV vaccination is allergic reaction to any 
component of the vaccine. 2  Furthermore, it is important to recognize that HPV transmission can 
occur in a variety of ways including hand transmission 11, and HPV can be found in children 
prior to any sexual activity.12 For these reasons, all adolescents should receive HPV vaccination 
at the recommended age regardless of past medical history.  In females with special needs, 
cervical cancer screening may also prove more difficult, making HPV vaccination a priority.   
In both control and affected populations, parents placed high importance on vaccines in regards 
to their child’s health, and felt that vaccines were overall safe.  However, this contradicts reasons 
that they gave for nonvaccinaction such as “concern for safety” or “not needed”.  It is possible 
that this is because parents may view HPV vaccination differently from other scheduled 
vaccines.  In both populations, lack of a recommendation from a medical provider was one of the 
primary reasons for not getting their child vaccinated.  Provider attitudes were not assessed in 
our study; however, a prior study found that providers caring for females with special needs 
placed a high priority on recommended vaccinations.8  It has been well documented that a 
provider recommendation is the most influential factor in a patient’s decision to receive an 
immunization, and that more parents of vaccinated teens reported receiving a recommendation 
compared with parents of unvaccinated teens.13  
It is important to recognize populations at risk for missed vaccination opportunities.  HPV 
vaccination should be recommended to all adolescents at the target age, including those with 
physical and mental limitation.  Future directions would include study on improving provider 
recommendations, and provider and parent awareness of HPV vaccination in underserved 
populations such as those with mental and physical limitation.  
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